Nanobiotix Reports Nanoprimer Breakthrough at AACR 2026
PARIS, France & CAMBRIDGE, USA, April 20, 2026 Nanobiotix has unveiled promising preclinical data demonstrating that its Nanoprimer technology...
Immunotherapy
Advertisement
Marengo Reports Phase 2 Breast Cancer Data at AACR
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics, Inc. announced late-breaking Phase 2 clinical results for its investigational immunotherapy invikafusp...
City of Hope Unveils AI and Cancer Breakthroughs at AACR
LOS ANGELES, April 16, 2026 City of Hope announced that its scientists will present groundbreaking research findings on cancer...
Janux Therapeutics Doses First Patient in JANX014 Study
SAN DIEGO, USA, April 16, 2026 Janux Therapeutics, Inc. has announced a key clinical milestone with the first participant...
AIM ImmunoTech Advances Ampligen Phase 3 Cancer Trial
OCALA, Fla., April 16, 2026 AIM ImmunoTech Inc. has announced significant progress in its oncology pipeline, entering a pivotal...
Advertisements
MAIA Activates U.S. Site for Phase 2 Lung Cancer Trial
CHICAGO, April 16, 2026 MAIA Biotechnology, Inc. has announced the activation of its first U.S. clinical site for the...
Fate Therapeutics FT839 CAR T Shows Strong Preclinical Data
SAN DIEGO, Calif., April 16, 2026 Fate Therapeutics, Inc. has announced the presentation of preclinical data for its next-generation...
Geminii Shows Promising NSCLC Data for Bioelectronic Therapy
CHICAGO, April 16, 2026 Geminii, Inc. has announced the presentation of new preclinical data on its bioelectronic therapy platform...
PDS Biotech Reports Breakthrough Phase 2 mCRC Results
Princeton, New Jersey, U.S. | April 15, 2026 PDS Biotechnology has announced the publication of positive interim Phase 2...
Immutep Secures FDA Orphan Status for Efti in Sarcoma
Sydney, Australia | April 15, 2026 Immutep Limited has achieved a significant regulatory milestone with the U.S. Food and...
Advertisement
